A

Industry Internship Project

On

Dr reddy’s laboratories

SUBMITTED BY:TEJNARAYAN SINGH CHANDRA

(MKT + IT 2009-2011)

SURYADATTA INSTITUTE OF MANAGEMENT AND MASS

COMMUNICATION (SIMMC), PUNE

ACKNOWLEDGEMENT

It is my pleasure to be indebted to various people, who directly or indirectly contributed in the

development of this work and who influenced my thinking, behavior and acts during the course

of project.

I express my heartiest thanks to Mr. S. B. Choradiya(Director SIMMC/SIBMT) for

providing us such an opportunity of making industry project & sparing his valuable time to

undertake this project and giving us real industrial exposure through this winter project.

I am also extremely grateful to Mr. S. B. Choradiya for giving invaluable inputs as well as

moral support which helped us in successful completion of the project report.

I would also like to thank all the persons who has been associated directly or indirectly

with this project and helped me in getting this present form.

TEJNARAYAN SINGH CHANDRA

DECLARATION

I, Tejnarayan Singh Chandra student of Suryadatta institute of management & mass

communication (simmc) do hereby solemnly and sincerely declare, to the best of my knowledge

and belief, as follows:

This is to certify that I am responsible for all data which I have used to making this

report.I have made report under consideration of my project guide.I am lawfully entitled to the

use of the trade mark of which the said description is a true description.

 

NAME: Tejnarayan Singh Chandra

DATE: 24/07/2010

 

CERTIFICATE

Contents

Title page

Acknowledgement---------------------------------------------------------- 2 Declaration------------------------------------------------------------------- 3 Certificate-------------------------------------------------------------------- 4

Introduction------------------------------------------------------------------- 5 Sector profile----------------------------------------------------------------- 6 The Indian Pharmaceutical industry today------------------------------- 7 Major players of pharmaceuticals----------------------------------------- 10 Dr Reddy’s Laboratories:

Industry background--------------------------------------------------------11 Company profile------------------------------------------------------------ 12 Board of directors------------------------------------------------------------13 Organizational structures----------------------------------------------------13 Code of conduct--------------------------------------------------------------14 History ------------------------------------------------------------------------16 Global presence --------------------------------------------------------------17 Milestones --------------------------------------------------------------------18 Business overview-----------------------------------------------------------20 Manufacturing and R&D facilities----------------------------------------22 Financial analysis------------------------------------------------------------23 Shareholding pattern--------------------------------------------------------24 Balance sheet-----------------------------------------------------------------25 Products ----------------------------------------------------------------------26 Exports -----------------------------------------------------------------------31 Competitors ------------------------------------------------------------------31 Investment rationale---------------------------------------------------------32 Marketing strategies---------------------------------------------------------33 Recent news------------------------------------------------------------------34 Major achievements---------------------------------------------------------34

Conclusion--------------------------------------------------------------------- 37 Learning experience---------------------------------------------------------- 37

Pharmaceutical industries

INTRODUCTION

Health is defined both as cause and effect of economic development. Therefore, the pharmaceutical industry is specifically recognized in the UN Millennium Development Goals as an actor that can contribute to economic development. In addition, the pharmaceutical industry provides significant socio-economic benefits to the society through creation of jobs, supply chains, and through

community development.The industry also plays an important role in technological innovation, which may reduce costs of economic activity elsewhere in the economy.

Players in the pharmaceutical industry include: branded drug manufacturers, generic drug manufacturers, firms developing biopharmaceutical products, nonprescription drug anufacturers, firms undertaking contract research. In addition, there are also enablers of the industry such as universities, hospitals and research centers that play a role in R&D activities.

INDIAN PHARMA INDUSTRY

The Indian pharmaceutical industry is the world's second-largest by volume and is likely to lead the manufacturing sector of India. The first pharmaceutical company are Bengal Chemicals and Pharmaceutical Works, which still exists today as one of 5 government-owned drug manufacturers, appeared in Calcutta in 1930. Playing a key role in promoting and sustaining development in the vital field of medicines.

Indian Pharma Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world.

The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units with severe price competition and government price control. It has expanded drastically in the last two decades.

There are about 250 large units that control 70 per cent of the market with market leader holding nearly 7 per cent of the market share and about 8000 Small Scale Units together which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations. The total Indian production constitutes about 13 per cent of the world market in value terms and, 8 per cent in volume terms. The per capita consumption of drugs in India, stands at US$3, is amongst the lowest in the world, as compared to Japan- US$412, Germany- US$222 and USA- US$191.

EVOLUTION OF INDIAN PHARMACEUTICAL INDUSTRY

The Indian pharmaceutical industry has come a long way since the time of independence when multinational corporations dominated the industry Over the years, under a favourable policy regime, the industry has grown phenomenally and has established itself as a major supplier of not only generic products but also new formulations. The industry, in addition to meeting domestic demand, is in a position to export significant volume of pharmaceutical products to various destinations,including the developed markets of USA, EU and Japan.

Evolution of Indian pharmaceutical industry can be classified into the following three periods:

Pre-1970s: During this period, the size of Indian pharmaceutical industry was small, both in terms of number of firms and volume of production. MNCs dominated the market, both in terms of volume of production and patent holdings, in India. The patent regime, based on Indian Patents and Designs Act, 1911, recognized both product and process patents. Due to monopoly status enjoyed by the MNCs, drug prices remained high during this period.

1970 – 1995: Government of India introduced a new Patent Act, which came into effect in 1972, recognizing only process patent and not product patent. The Act enabled Indian firms to use ‘reverse engineering process’, to manufacture drugs, without paying royalty to the original patent holder. The

Act, along with Drug Price Control. Order, provided little incentive for MNCs to introduce new pharmaceutical products in India. During this period, the number of domestic pharmaceutical firms increased considerably, from around 2000 units in 1970 to 24,000 units in1995.

1995 onwards: The year 1995 recorded another milestone for the Indian pharmaceutical industry. One of the Agreements under the World Trade Organisation was complying with the Trade Related Intellectual Property Rights (TRIPS) provisions. The TRIPS Agreement reintroduced product patent in India. Further, during this period, tariff and non-tariff measures have come down. Such developments have worked in favour of Indian pharmaceutical industry to undertake activities such as clinical research and new drug development. Indigenous producers dominated the market accounting for more than 70% of the market share. Exportsalso continued to increase during this period, due to strong R&D process and low manufacturing cost.

SUCCESS STRATEGIES OF INDIAN PHARMACEUTICAL INDUSTRY

“The Indian pharmaceutical industry is a success story providing employment for millions and ensuring that essential drugs at affordable prices are available to the vast population of this sub-continent.”

Richard Gerster

Indian pharmaceutical industry, utilizing the policy environment prevailing over the years, adopted various strategies to surge as a global player. These include:

Increasing R&D Activities:Since the formation of WTO and signing of TRIPS Agreement, Indian pharmaceutical industry is increasingly becoming innovative rather than imitative. The players are changing their R&D strategy from ‘reverse engineering’ to ‘patent driven’. R&D expenditure as a percentage of sales, which stood at around 2% in 1993-94, increased to around 5% in 2005-06.

Increasing Filings with USFDA:With an increase in R&D spending, Indian companies could file large number of Drug Master Files and Abbreviated New Drug Application) with US-FDA. According to Organization of Pharmaceutical Producers of India, India accounted for largest number of Drug Master Files with US-FDA.

Public-Private Partnership in R&D:Many Indian pharmaceutical firms, in addition to undertaking in-house R&D activities, are collaborating with research laboratories such as Central Drug Research Institute (CDRI), Lucknow; Indian Institute of Chemical Technology (IICT), Hyderabad; and Centre for Cellular and Molecular Biology (CCMB), Hyderabad.

Leveraging Biotechnology:

Biotechnology is one of the areas that are showing promising future. Biotechnology drugs represent a significant part of the new innovative medicines launched worldwide. Bio-pharmaceuticals account for more than 10% of global pharmaceutical sales. Many Indian pharmaceutical firms are leveraging the potential of biotechnology including manufacture of biogenerics.

Diversification of Markets:Over the years, Indian pharmaceutical firms have been successful in exporting pharmaceutical products to traditional as also new destinations.

Contract Research:Given the pressing need of global pharmaceutical industry to develop new drugs, major pharmaceutical producers across the globe are looking out for sourcing R&D activities. Indian companies are undertaking contract research (including drug discovery, preclinical and clinical research) for global pharmaceutical majors leveraging the prevailing advantages such as:

Already well-developed pharmaceutical manufacturing base;Low R&D cost; Availability of highly qualified man-power; Large patient pool for clinical trials.

Contract Manufacturing:New start-up companies are increasingly getting international exposure through the contract manufacturing (of patented drugs, custom synthesis and scale-ups, specialized generics and old molecules) route. It is estimated that about 50% of global bulk drugs / API manufacturing and around 15% of formulations manufacturing are outsourced to low cost destinations.

Co-Marketing Alliances:Another growth strategy adopted by Indian firms is entering into comarketing alliances with foreign firms to market their products. Such alliances are proven to be beneficial to both the parties.

Strengthening R&D:It is important for Indian pharmaceutical industry to scale up their R&D intensity to strengthen their position in the global market place.

Safety and Quality: Menace of Spurious drugs:Ensuring safety and quality of pharmaceutical products is another major concern, especially in the context of alleged prevalence of spurious drugs

Pricing strategies:it is crucial to consider optimal pricing strategies while determining the viability of launching a drug.The need for viable pricing strategies also increases in an era of rising R&D costs.

Skill Development:

Pharmaceutical industry is highly R&D intensive. In order to remain globally competitive the industry requires pool of highly skilled manpower. India has already made its mark in scientific research in the world with large pool of scientific man-power.

Domestic DemandThe industry has enormous growth potential. Factors listed below determine the rising demand for pharmaceuticals.• The growing population of over of a billion• Increasing income• Demand for quality healthcare service• Changing lifestyle has led to change in disease patterns, and increased demand for new medicines to combat lifestyle related diseases.

ExportsOver 60 per cent of India’s bulk drug production is exported. Domestic pharmaceutical exports, growing at 30 % per annum, touched a new height of US$4.8 billion in the financial year 2006-07. The export revenue now contributes almost half of the total revenue for the top three pharmaceutical majors: Dr Reddy’s, Ranbaxy and Cipla..

PRESENT STATUS OF INDIAN PHARMACEUTICAL INDUSTRY:

Indian pharmaceutical industry is one of the fastest growing segments of Indian manufacturing sector. The pharmaceutical industry has experienced a growth rate of 12% with the annual turnover of the sector crossing US$ 11 billion, in 2005-0614. Globally, Indian pharmaceutical industry ranks 4th in terms of volume with a share of 8% in the world pharmaceuticals market. In terms of value, Indian pharmaceuticals industry ranks 14thThe annual turnover of the Indian pharmaceutical industry is over US$ 11 billion. Globally it ranks 4th in terms of volume with a share of 8% in the world pharmaceutical market. In terms of value, it ranks 14th. Key therapeutic segments of Indian pharmaceutical industry include anti-infective, gastrointestinal and cardio-vascular. Acute therapies make up about 60% of the market. However, it is expected that with the changing lifestyle and aging population, sales of chronic therapies (i.e. diabetes, cardiovascular) are growing rapidly The pharmaceutical industry is also showing good performance in terms of exports. It is one of the top export items from India accounting for more than 4% of India’s total exports in 2006-07. Exports, which constitute around 50% of the industry’s total production, have grown at a CAGR of 14% in the last decade. Major export markets include highly regulated markets such as USA, Germany, UK and canada. Europe is the biggest export destination for Indian pharmaceuticals accounting for more than 30% of the total exports, followed by the Americas region (25%).

. Indian pharma’s Current Status of growth

India's US$ 9.4 billion pharmaceutical industry is growing at the rate of 14 percent per year. It is one of the largest and most advanced among the developing countries. The Indian pharmaceutical industry can reach a market size of US$ 11.6 billion by 2009.

COMPETITION OVERVIEW

Major Players in the Pharmaceuticals Industry

Competition is mainly from the domestic manufacturers and imports from China because of the low manufacturing cost. With the new patent regulations the industry expects to see a major structural shift with the entry of foreign pharmaceutical manufacturers

There are five government-owned companies of the Indian public sector. These companies are the Indian Drugs and Pharmaceuticals, Hindustan Antibiotics Limited, Bengal Chemicals and Pharmaceuticals Limited, Bengal Immunity Limited and Smith Stanistreet Pharmaceuticals Limited. Some of the major Indian private companies are Alembic Chemicals, Aurobindo Pharma, Ambalal Sharabhai Limited, Cadila Healthcare, Cipla, Dr. Reddy’s, IPCA Laboratories, Jagsonpal Pharma, J.B. Chemicals, Kopran, Lupin Labs, Lyka Labs, Nicholas Piramal, Ranbaxy Labs, Matrix Laboratories, Orchid Chemical and Pharmaceuticals, Sun Pharmaceuticals, Ranbaxy Laboratories, Torrent Pharma, TTK Healthcare, Unichem Labs, and Wockhardt.

Dr Reddy’s laboratories

Type : Public

Industry : Pharmaceuticals

Founded : 1984

Headquarters : Hyderabad, Andhra Pradesh, India.

Key People : Anji Reddy (chairman), G V Prasad (CEO)

Revenue : $1.565 billion (2010)

Net Income : $23 million (2010)

Employees : 13,455 (2010)

Website : www.drreddys.com

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NYSE: RDY) founded in 1984 by Dr. K. Anji Reddy, has become India's second biggest pharmaceutical company. Dr. Anji Reddy had worked in the publicly-owned Indian Drugs and Pharmaceuticals Ltd. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology products.

Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration (FDA). By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.

By 2007, Dr. Reddy's had six FDA-plants producing active pharmaceutical ingredients in India and seven FDA-inspected and ISO 9001 (quality) and ISO 14001 (environmental management) certified plants making patient-ready medications – five of them in India and two in the UK.

In 2010, the family-controlled Dr Reddys denied that it was in talks to sell its generics business in India to US pharmaceutical giant Pfizer, which had been suing the company for alleged patent infringement after Dr Reddys announced that it intended to produce a generic version of Atorvastatin, marketed by Pfizer as Lipitor, an anti-cholesterol medication. Reddys was already linked to UK pharmaceuticals multinational Glaxo Smithkline.

About Dr Reddy's laboratories

Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. As a fully integrated pharmaceutical company, our purpose is to provide affordable and innovative medicines through our three core businesses:

Pharmaceutical Services and Active Ingredients, comprising our Active Pharmaceuticals and Custom Pharmaceuticals businesses;

Global Generics, which includes branded and unbranded generics; and Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated Formulations, and

Generic Biopharmaceuticals

Our products are marketed globally, with a focus on India, US, Europe and Russia. Dr. Reddy’s conducts NCE research in the areas of metabolic disorders, cardiovascular indications, anti-infectives and inflammation.

Our strong portfolio of businesses, geographies and products gives us an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world, regardless of geographic and socio-economic barriers

Purpose: Committed to providing Affordable and Innovative medicines for healthier lives.

Affordability

The high cost of many medicines puts them out of the reach of millions of people who desperately need them. As a global pharmaceutical company, we take very seriously our responsibility to help alleviate the burden of disease on individuals and on the world. Through our Global Generics business, we provide high quality, lower-cost alternatives to innovator drugs. Our wide range of generic medicines bring hope and health to people around the globe

Innovation

Despite the great advances of medical science, there are still far too many diseases for which there are no cures or no satisfactory treatments. We believe that innovation – in research, processes and technologies – holds the key to finding solutions for unmet or inadequately met medical needs. Our Proprietary Products business is dedicated to discovering new or better treatments than currently exist. In addition, our Custom Pharmaceutical Services business works with Innovator companies and emerging biotech firms to accelerate the development of new molecules, while lowering research costs

Capabilities:

Deep Manufacturing Expertise

We have 16 world-class manufacturing facilities of which 9 have a long history of regular USFDA inspections. With an annual capacity of nine billion tablets/ capsules a year, dedicated to servicing the more regulated markets, one of our finished dosages facilities is among the largest in Asia. Our facilities are designed to respond to a wide range of technologies - oral solids, injectibles, topicals, inhalers, cytotoxic, hormonals and other dosage forms.

Such manufacturing capabilities and our inherent expertise to navigate intellectual property road blocks make us a preferred partner for some of the world’s leading pharmaceutical companies

Globally synchronized supply chain

We put the needs of our partners and customers first. Our globally synchronized supply chain and a comprehensive Information technology platform help us assure customers of timely delivery and superior inventory turns. The uninterrupted success of our customers’ business is our promise.

Regulatory Performance

Over the years we have built an expertise in understanding the regulatory frameworks of the various countries in which we operate. This has given us a distinctive edge, for ourselves and our customers. We have built a successful track record of timely and extensive approvals. As an example, we are among the leaders in terms of DMFs and ANDAs in the US itself, with more than half of these being Para IV possibilities.

Quality & Product Responsibility

At Dr Reddy’s, we strictly follow quality control and quality assurance systems as specified by regulatory requirements in each of the geographies in which we operate. For us, product responsibility extends through the life cycle of the product -- from product development to manufacture to product release to post-launch. We comply with the internationally accepted International Conference on Harmonization (ICH) guidelines in product development and we have independent quality control and quality assurance teams to ensure multi-stage quality compliance

Business:

Humanity’s health needs are greater than any one company’s ability to solve them; yet we can work with others to bring new drugs quickly to the market and provide the building blocks of affordable medicines. Through our PSAI business, which comprises the Active Pharmaceutical Ingredients (API) and Custom Pharmaceutical Services (CPS) businesses, we offer IP advantaged, speedy product development and cost-effective manufacturing services to our customers – generic companies and innovators. This allows us to help make good medicines available to more people around the world. The core strengths of our PSAI business are the state-of-the-art infrastructure, resources and skills we are able to offer to our customers:

Large and diverse product portfolio Eight FDA-inspected plants and three technology centers World class chemistry expertise Robust, large-scale manufacturing capabilities Intellectual Property (IP) driven product development for freedom to operate Total, seamless supply chain management

Corporate office

Dr. Reddy's Laboratories Ltd.8-2-337, Road No 3,

Banjara Hills, Hyderabad - 500034, Andhra Pradesh - INDIA

Tel: +91-40-23731946 / 47 / 48 / 49 / 50Fax: +91-40-23731955

Visit: www.drreddys.com

Active Pharmaceutical IngredientsDr. Reddy's Laboratories Ltd.

8-2-120/76/1/B, 2nd Floor,Ashoka Hitec Chambers,

Road No. 2, Banjara Hills, Hyderabad,INDIA - 500 034

Tel: +91 40 66470960Fax: +91 40 23541224 Email: apiinquiry@drreddys.com

Business DevelopmentDr. Reddy's Laboratories Ltd.

Greenlands, Ameerpet,Hyderabad 500 016, INDIA

Tel: +91-40-23731946/47/48/49/50Fax: +91-40-23731955

Email: businessdevelopment@drreddys.com

Dr. Reddy's FoundationDr. Reddy's Foundation6-3-655/12, Somajiguda,

Hyderabad-500082.

Tel: +91-40-65343424, 23304199 / 1868Fax: +91-40-23301085

E-mail: info@drreddysfoundation.orgVisit: www.drreddysfoundation.org

Board of Directors

Dr. Reddy’s Board of Directors comprises eminent individuals from diverse fields. The Board acts with autonomy and independence in exercising strategic supervision, discharging its fiduciary responsibilities,

and in ensuring that the management observes the highest standards of ethics, transparency and disclosure.Our directors are experts in the diverse fields of medicine, chemistry and medical research human resource development, business strategy, finance, and economics. They review all significant business decisions, including strategic and regulatory matters. Every member of the Board, including the non-executive directors, has full access to any information related to our company.Committees appointed by the Board focus on specific areas, take decisions within the authority delegated to them and make specific recommendations to the Board on matters in their areas or purview.

WHOLE-TIME DIRECTORS

Dr. K. Anji Reddy G V Prasad Satish ReddyChairman Vice Chairman and Managing Director & Chief

Chief Executive Officer Operating Officer

INDEPENDENT & NON WHOLE TIME DIRECTORS

Dr. Omkar Goswami Ravi Bhoothalingam Dr. Bruce LA Carter

Anupam Puri Ms.Kalpana Morparia J.P. Moreau Dr. Ashok Ganguly

SUSTAINABILITY:

At Dr. Reddy’s, sustainability is a multi-dimensional aspiration, which has its roots in the very purpose of our existence – providing affordable medicines to people around the world and meeting unmet medical

needs through innovation. Our business, by its very nature, serves a social good, so we have a far deeper reason than profits alone to drive our performance.

For us, building a sustainable organization is not a trend we blindly follow; it is intrinsic to how we have operated for decades. To us, a commitment to sustainability means a commitment to fulfilling our obligations to all of our stakeholders -- our customers & partners, employees, shareholders and society. Thus, while optimizing profitability may be one measurement of our performance, we also judge our success by our performance with regard to the communities in which we live and work, the environment and our employees. We understand that it is only by increasing value to all of these stakeholders that we can build an ever flourishing and lasting organization.

While sustainability thinking was always woven into the fabric of our organization, we formally declared our intent to institutionalize it in 2004, when we first began to publicly report on our sustainability practices.  We annually publish our Sustainability Report with direction from the guidelines recommended by Global Report Initiative G3, covering social, ethical, economic, safety and environmental aspects of our business.

MERGER AND ACQUISITION

Dr Reddy's Laboratories Ltd acquires GlaxoSmithKline-Penicillin Bus from GlaxoSmithKline PLC - March 30, 2011

Dr Reddys Laboratories Ltd acquires remaining interest in Perlecan Pharma Pvt Ltd. Sept 18, 2009.

Dr Reddys Laboratories Ltd acquires Dowpharma-small molecules from Dow Chemical co. April 30, 2008.

Dr Reddys Laboratories Ltd acquires remaining interest in Perlecan Pharma Pvt Ltd.-july 30, 2008

Dr Reddys Laboratories Ltd acquires Betapharm Arzneimittel GmbH from 3i Group PLC – March 04, 2006.

Watson Pharmaceuticals Inc acquires Dr Reddys Lab Ltd-Formulation from Dr Reddys Laboratories Ltd- Dec 16, 2005

Dr Reddys Laboratories Ltd acquires Trigenesis Therapeutics Inc – May 06, 2004

Dr Reddys Laboratories Ltd acquires BMS Laboratories Ltd- April 01, 2002

Dr Reddys Laboratories Ltd acquires Dai-Ichi-Women's Health Brands from Dai-Ichi Karkaria Ltd – Sep 14, 2000.

Alliance and Partnership

Our Partnering Philosophy

At the core of each successful partnership is a great relationship based on trust and mutual respect. As we work towards fulfilling our core purpose we share your aspirations. We recognize and embrace the fact that our partners are a core component of this strategy.

We understand that partnerships are successful when benefits accrue to both parties. They are built on a shared vision with well-defined and agreed-upon goals. We also know that that the partners’ thinking and interests may not always be identical, but that we share the same goal—a successful product.

Our shared partnership successes are at the very heart of our business. From our first meeting through product launch and beyond, we stand behind our belief in true partnership thereby combining our strengths and sharing our successes. Dr. Reddy's firmly believes that the right alliances can contribute significantly to the success of our partners as well as to our own strategy and sustainable growth

Transparent and Simple process

Clarity of thought, Speed of execution, Flexibility, creativity, and transparency are critical components of our negotiation and transaction process. As no two deals are the same, we work with potential partners to structure deals through customized approaches that allow both partners to leverage unique capabilities and assets in order to achieve common goals.

A simple and streamlined process to progress our partnering discussions and a flat organizational structure facilitates rapid decision making from initial screening to execution.

As a company that evaluates 100+ business development opportunities in any given year (many of which come to closure), we value the time and resources our potential partners commit to explore and complete any potential partnership. Dr. Reddy’s emphasizes a transparent and collaborative negotiation process and prompt decision making.

We bring a reputation for acting swiftly and being flexible. We will work with you to reach an agreement with which you will be comfortable and that will head us in the right direction toward shared success.

Sustained relationship based on trust and mutual respect:

Our robust alliance management principles and practices allow successful execution of joint initiatives.Dr. Reddy’s is committed to ensuring that our partnerships succeed and flourish.